Hospital
Carilion Franklin Memorial Hospital
Carilion Franklin Memorial Hospital was paid $18.38M by Medicaid between Jan 2018 and Dec 2024, across 194 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoCARILION FRANKLIN MEMORIAL HOSPITAL
ROCKY MOUNT, VA 24151
ROCKY MOUNT, VA 24151
33aNPI1710970918assigned 08/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.38M
24GClaims434,132
24DCodes billed194
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#36 of 80
Median peer was paid$14.69M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GRISETTI, NICOLE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,931 | $1.18M | |
| 2019 | 61,658 | $2.18M | |
| 2020 | 53,438 | $2.06M | |
| 2021 | 66,553 | $2.52M | |
| 2022 | 70,099 | $3.13M | |
| 2023 | 80,053 | $3.85M | |
| 2024incomplete | 63,400 | $3.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 20,450 | 18,340 | $3.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 16,828 | 14,586 | $3.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 8,256 | 6,990 | $2.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 10,563 | 9,168 | $2.00M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 6,462 | 5,942 | $1.04M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 4,299 | 3,959 | $965K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 12,596 | 3,443 | $675K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 3,324 | 3,000 | $537K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 6,307 | 5,816 | $422K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 2,223 | 2,027 | $334K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,497 | 1,371 | $286K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 1,143 | 1,003 | $282K |
182 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 1,239 | $255K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.2% | 2,005 | $212K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 3,040 | $205K |
| 76830 | Ultrasound, transvaginal | <1% | 1,331 | $150K |
| 97162 | <1% | 877 | $137K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,820 | $124K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 552 | $123K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 461 | $118K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,962 | $108K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 701 | $107K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,702 | $105K |
| 97161 | <1% | 812 | $78K | |
| 80053 | Comprehensive metabolic panel | <1% | 19,169 | $71K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 628 | $67K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 285 | $62K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 141 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,082 | $51K |
| 93971 | <1% | 500 | $49K | |
| 99220 | <1% | 1,041 | $45K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 709 | $38K |
| 73630 | <1% | 1,891 | $36K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 304 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,694 | $34K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 42 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,107 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,360 | $29K |
| 76536 | <1% | 225 | $25K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 537 | $22K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,989 | $22K |
| 74018 | <1% | 1,066 | $20K | |
| 94060 | <1% | 223 | $20K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,092 | $18K |
| 70496 | <1% | 58 | $17K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 963 | $16K |
| 73610 | <1% | 1,270 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,325 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 43 | $15K |
| 83880 | <1% | 2,010 | $15K | |
| 72100 | <1% | 778 | $15K | |
| 71250 | <1% | 214 | $14K | |
| 10060 | <1% | 63 | $14K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,790 | $14K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 192 | $12K |
| 84484 | <1% | 9,375 | $11K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,834 | $11K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 725 | $11K |
| 87040 | <1% | 1,618 | $9K | |
| 80047 | <1% | 2,230 | $7K | |
| 73030 | <1% | 669 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,595 | $7K |
| 73564 | <1% | 963 | $7K | |
| 94726 | <1% | 152 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 748 | $7K |
| 94729 | <1% | 174 | $7K | |
| 73130 | <1% | 719 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $7K |
| J3490 | Unclassified drugs | <1% | 22,855 | $6K |
| 72141 | <1% | 25 | $6K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,322 | $6K |
| 90715 | <1% | 270 | $5K | |
| 12001 | <1% | 25 | $5K | |
| 82565 | <1% | 1,202 | $5K | |
| 97014 | <1% | 123 | $4K | |
| 70491 | <1% | 12 | $4K | |
| 70498 | <1% | 97 | $4K | |
| 85610 | <1% | 2,481 | $3K | |
| 83605 | <1% | 2,669 | $3K | |
| 99234 | <1% | 372 | $3K | |
| 85379 | <1% | 890 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,282 | $3K |
| 71271 | <1% | 27 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,736 | $2K |
| 81025 | <1% | 3,908 | $2K | |
| 97163 | <1% | 12 | $2K | |
| 82962 | <1% | 4,552 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 416 | $2K |
| 84703 | <1% | 3,338 | $2K | |
| 81001 | <1% | 9,378 | $1K | |
| 73110 | <1% | 258 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,303 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 745 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,789 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 207 | $940.30 |
| 70486 | <1% | 12 | $828.09 | |
| 83690 | <1% | 6,100 | $777.67 | |
| 80076 | <1% | 347 | $739.41 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 33 | $713.41 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,085 | $691.37 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 936 | $603.78 |
| 83735 | <1% | 4,348 | $548.14 | |
| 84702 | <1% | 579 | $544.69 | |
| 85014 | <1% | 2,330 | $531.69 | |
| 80306 | <1% | 357 | $490.64 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,203 | $469.57 |
| 80179 | <1% | 74 | $466.28 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,619 | $464.74 |
| 72131 | <1% | 12 | $434.26 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,607 | $420.19 |
| 73590 | <1% | 76 | $401.96 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,757 | $398.15 |
| 80143 | <1% | 106 | $394.23 | |
| 85027 | <1% | 155 | $389.61 | |
| 82803 | <1% | 445 | $388.78 | |
| 96376 | <1% | 4,048 | $381.59 | |
| 86900 | <1% | 427 | $365.15 | |
| 73502 | <1% | 56 | $363.43 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,332 | $358.86 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,634 | $358.81 |
| 81003 | <1% | 3,568 | $356.60 | |
| 87186 | <1% | 1,515 | $325.65 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $321.79 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,553 | $243.86 |
| 87210 | <1% | 401 | $207.33 | |
| 36416 | <1% | 201 | $200.81 | |
| 86850 | <1% | 304 | $193.93 | |
| 74022 | <1% | 42 | $189.30 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,049 | $189.02 |
| 87077 | <1% | 1,028 | $177.09 | |
| 86140 | <1% | 1,046 | $164.05 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 168 | $155.34 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,353 | $148.72 |
| 86901 | <1% | 540 | $138.71 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $136.97 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 390 | $132.82 |
| 87081 | <1% | 1,304 | $129.63 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 413 | $124.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,393 | $119.09 |
| 73140 | <1% | 12 | $111.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,985 | $103.98 |
| 85652 | <1% | 1,033 | $91.72 | |
| 85730 | <1% | 501 | $66.03 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,373 | $64.95 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 907 | $57.33 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,333 | $52.16 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 15,437 | $44.08 |
| G0378 | Hospital observation service, per hour | <1% | 35 | $43.82 |
| 82550 | <1% | 201 | $43.08 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 356 | $41.06 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 344 | $39.29 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 108 | $37.88 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 254 | $35.16 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 475 | $33.87 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 929 | $27.42 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 93 | $23.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 586 | $20.24 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 765 | $20.04 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 394 | $18.60 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 110 | $9.53 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46 | $9.49 |
| J1815 | Injection, insulin, per 5 units | <1% | 36 | $3.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 13 | $2.44 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 14 | $2.43 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 21 | $1.78 |
| S0028 | Injection, famotidine, 20 mg | <1% | 215 | $1.78 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 232 | $1.68 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 627 | $0.00 |
| 94644 | 0% | 57 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 167 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 450 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 360 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 29 | $0.00 |
| 84132 | 0% | 28 | $0.00 | |
| 87807 | 0% | 29 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 22 | $0.00 |
| A9270 | Non-covered item or service | 0% | 16 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 54 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 48 | $0.00 |
| 96368 | 0% | 27 | $0.00 | |
| 87088 | 0% | 20 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,432 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 73 | $0.00 |
| 94664 | 0% | 92 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 209 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 22 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 93 | $0.00 |
| 82272 | 0% | 14 | $0.00 | |
| 96367 | 0% | 14 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRISETTI, NICOLE (DIRECTOR OF OPERATIONAL SUPPORT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.